Despite growing recognition of type 2 myocardial infarction (T2MI; related to supply/demand mismatch), little is known about its risk factors or its association with outcome.
S
ignificant effort has been devoted to optimizing recognition and management of myocardial infarction (MI). In an effort to address the clinical heterogeneity in affected patients, recent consensus documents have defined 5 MI types; of these, the 2 most common are classical type 1 MI, attributable to acute coronary artery plaque rupture and thrombosis, and type 2 MI (T2MI), defined as MI consequent to myocardial demand-supply mismatch.
1 Among studies of patients with documented MI, the proportion of T2MI may be as high as 48%, 2 ,3 yet surprisingly little is known about its characteristics and clinical significance. Because of this, along with a lack of defined treatment strategy for patients diagnosed with T2MI, such patients are frequently treated with lower urgency, in stark contrast to type 1 MI. It is most worrisome that emerging data have suggested that T2MI may not be a clinical or laboratory nuisance, but a complex syndrome deserving better clarity of characterization and prognostic significance; such clarity might lead to defined approaches for care of patients with this prevalent syndrome. [4] [5] [6] To better understand T2MI, we prospectively conducted a clinical registry of patients undergoing coronary or peripheral angiographic procedures, evaluating the incidence of T2MI during follow-up, identifying its predictors, and evaluating the prognosis for a broad range of outcomes after incident T2MI.
METHODS
All study procedures were approved by the Partners Healthcare Institutional Review Board and performed in accordance with the Declaration of Helsinki.
Study Design and Participants
The design of the CASABLANCA study (Catheter Sampled Blood Archive in Cardiovascular Diseases) (ClinicalTrials.gov NCT00842868) has been described previously and is summarized in Figure 1 . 7 The study was a single-center prospective cohort study in consecutive patients aged ≥18 years undergoing coronary and peripheral angiographic procedures (with or without vascular intervention). Enrollment was performed during normal business hours at the Massachusetts General Hospital in Boston between 2008 and 2011 After written informed consent was obtained, detailed clinical and angiographic data at the time of the procedure were recorded. The left main, left anterior descending, left circumflex, and right coronary arteries were each considered major coronary arteries; the highest percentage of stenosis within each major coronary artery and branches was obtained from angiography reports.
Fifteen milliliters of blood was taken immediately before and immediately after the angiographic procedure (with or without intervention) through a centrally placed vascular access sheath. The blood was immediately centrifuged for 15 minutes; serum and plasma were aliquoted on ice and frozen at -80°C until biomarker measurement. The samples for this study were analyzed after the first freeze-thaw cycle for baseline biomarker values only (all Siemens, Inc). Serum was used for the following biomarkers, with the exception of myeloperoxidase
Clinical Perspective
What Is New?
• This is one of the first large systematic surveys of the frequency and implications of supply/demandrelated type 2 myocardial infarction (T2MI).
• T2MI is common, frequently recurrent, and associated with a poor prognosis, similar to type 1 myocardial infarction attributable to acute plaque rupture.
• Patients at risk for T2MI may be identified. Older age, higher blood pressure, coronary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, glucose, N-terminal pro-B-type natriuretic peptide, and cystatin C are independent risk markers.
What Are the Clinical Implications?
• Given the high frequency and poor outcomes in those with T2MI, better characterization and evaluation of treatment strategies is needed for this deleterious syndrome.
• Multidisciplinary care may be needed to best manage T2MI.
• T2MI may be even more recognized once high-sensitivity troponin assays become more widely used. 
Follow-Up and End Point Definitions
Patients were followed from the time of enrollment to the end of follow-up in 2015 with systematic medical record review. For identification of clinical end points, review of medical records and phone follow-up, as well, with patients and managing physicians was performed. The Social Security Death Index and postings of death announcements were used to confirm vital status. A detailed definition of end points for CASABLANCA has been published previously. 7 The following clinical end events were identified, adjudicated, and recorded by study investigators: allcause death, nonfatal MI, heart failure (HF), stroke, transient ischemic attack, peripheral arterial complication (as defined by progression of disease as classified by the Rutherford-Baker classification, and revascularization and amputation status [alive with 2 limbs without revascularization, alive with 2 limbs with surgical or percutaneous revascularization or interim amputation], as well), and cardiac arrhythmia (defined as any sustained ventricular tachycardia or fibrillation) not leading to defibrillator shock or cardiopulmonary resuscitation, and new or worsening supraventricular tachycardias including atrial flutter and atrial fibrillation requiring intervention, as well. These variables were grouped together as major adverse cardiovascular events (MACE). For any recurring events, each discrete event was recorded. In addition, deaths were adjudicated for the presence/absence of a cardiovascular cause.
MI Identification, Categorization of Subtypes, and Adjudication
For the purposes of follow-up event adjudication (online-only Data Supplement Figure I ), the entire cohort was divided among a group of study investigators (comprising 2 boardcertified cardiologists, 1 board-certified nurse practitioner, and 4 board-certified internists, all of whom have training in cardiology) and each investigator initially identified any potential MIs by using medical record search of clinically performed Guidance from the Third Universal Definition of MI was used to define MI and categories where MI was defined as symptoms and signs of myocardial ischemia complicated by myocardial necrosis; more specifically, detection of a rise and fall of cardiac troponin with at least 1 value above the 99th percentile of the upper reference limit or lowest troponin value associated with <10% imprecision and at least 1 supporting clinical evidence of MI including clinical symptoms, ECG changes indicative of ischemia, development of pathological Q waves, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. 8 MI diagnosis and category were determined by reviewing source documents from medical records, and contacting primary care physicians, as well, when there was missing information or to request further information. T2MI was defined as MI thought to be caused by an imbalance between myocardial oxygen supply and demand and not by acute coronary syndrome attributable to acute plaque rupture. Any diagnosis or categorization of uncertainty was discussed and consensus achieved at a weekly meeting in a committee of 2 board-certified cardiologists and 1 board-certified nurse practitioner trained in cardiology. When unanimous consensus was not reached, the case was presented to a senior cardiologist, who was not involved in the review and adjudication initially, for final decision. To validate the adjudication process, 10% of cases assigned T2MI diagnoses were randomly reviewed; 100% of cases met criteria for the diagnosis of T2MI (onlineonly Data Supplement Table I ).
Statistics
Categorical variables between groups were compared using the χ 2 test or the Fisher exact test as appropriate, and continuous variables were compared using the Student t, MannWhitney U, or Kruskal-Wallis test as appropriate. Normally distributed continuous variables were summarized using mean±standard deviation, whereas, in the context of nonnormality, median (25th, 75th percentile) was used.
The major end points in patients subsequent to first MI (including MACE, and the various constituents of MACE, as well) were assessed using landmark analyses to compare the rates of first events only where everyone with a prior history of any MACE before MI were censored. The follow-up time was adjusted according to the timing of the event relative to MI, and the incidence rates per 100 person-years were compared using the Poisson regression.
Cox proportional hazard models were used to analyze timeto-event data (including time to first T2MI, and clinical events, as well), expressing risk in terms of hazard ratio with 95% confidence intervals. Patients who did not experience an event were censored at the time of last contact or at the time of death. Age and sex were forced into all models and additional covariates were evaluated using the stepwise option for the selection (both stay and exit α=0.10). Continuous biomarker variables were log-transformed and standardized before the analysis. Comparison between survival curves was made using the log-rank test. In all statistical analyses, a 2-tailed P value of <0.05 was considered statistically significant. All analyses were performed using the SAS Version 9.4.
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RESULTS
During a median follow-up of 1234 days, 206 of 1251 (16.5%) patients had at least 1 MI; of these patients, 152 (73.8%) had at least 1 incident T2MI. Among those with T2MI, 56 (36.8%) had >1 T2MI, as shown in onlineonly Data Supplement Figure II . For most study participants experiencing >1 MI, regardless of the type of their index MI, almost all had subsequent T2MI. In contrast, it was rare for study participants with an initial T2MI to subsequently have other types of MI.
Baseline Characteristics of Those With and Without T2MI
In comparison with patients without T2MI, study participants who subsequently had incident T2MI were older, had more complex medical histories with prevalent comorbidities (including both cardiovascular and noncardiovascular diagnoses), and were treated more extensively for cardiometabolic diseases (Table 1) . Patients having an incident T2MI after enrollment were also more likely to have higher baseline myeloperoxidase, high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, and cystatin C concentrations.
A significant proportion of patients with T2MI had a history of prior coronary artery disease and prior revascularization procedures, whether with stents or bypass surgery. Accordingly, patients having incident T2MIs were more likely to have more diffuse coronary artery disease at the time of index angiography; for example, those with incident T2MI were more likely than those without to have ≥30% stenosis in at least 2 major coronary arteries (76.0% versus 59.2%, P<0.001, Table 1 ). Similar trends were seen with coronary stenoses of greater severity, and with coronary disease involving all coronary vessels, as well.
Multivariable Prediction of First T2MI
In a multivariable Cox regression analysis to identify predictors of incident T2MI following enrollment, older age, lower systolic blood pressure, history of coronary artery disease, HF, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, and higher glucose, N-terminal pro-B-type natriuretic peptide, and cystatin C, as well, were significant predictors of first T2MI (Table 2 ). There were no significant interactions between age or sex, and each additional covariate. Models by sex are demonstrated in online-only Data Supplement Table II , and models excluding those with MI at baseline and excluding those with type 4 MI are included as online-only Data Supplement Table III .
Clinical Outcomes After First T2MI
In comparison with those without, those experiencing incident T2MI subsequently had increased risk of nearly all end points collected (Figure 2A) Landmarked cumulative hazard curves expressing subsequent incidence of MACE, all-cause death, and cardiovascular death in those with and without T2MI are shown in Figure 3 . Cumulative hazard curves for subsequent incidence of MACE, all-cause death, and cardiovascular death in those with type 1 MI versus those with T2MI are shown in online-only Data Supplement Figure  III and for subsequent incidence of MI after type 1 MI and T2MI are shown in online-only Data Supplement Figure IV. In each case, hazard was significantly higher in those with T2MI than in those without (all P<0.001 with the exception of MACE where P=0.03). It is interesting that the cumulative hazard for each outcome (MACE, allcause death, and cardiovascular death) was essentially identical in subjects with T2MI only and those with type 1 MI only.
In multivariable, Cox regression analyses (Table 3) , incident T2MI was a strong independent risk factor for subsequent MACE (hazard ratio, 
DISCUSSION
Current consensus documents define T2MI as myocardial necrosis attributable to inequity between coronary blood flow delivery in the face of increased myocardial demand; an example of such an event includes signs and symptoms of coronary ischemia with a rise and fall of troponin concentrations in a patient with coronary artery disease and tachycardia because of medical illness. With widespread use of increasingly sensitive troponin assays, the recognition of T2MI has also increased. 9 In contrast to type 1 MI (most often attributable to acute plaque rupture and intracoronary thrombosis), which has defined risk factors, prognostic meaning, and wellarticulated treatment strategies, much less is known about the mechanistically different T2MI. Given such an absence of data, current consensus statements 1 and clinical practice guidelines for recognition and management of MI are silent with respect to the differentiation and treatment of this common and morbid diagnosis. 10, 11 Accordingly, patients with T2MI are more often managed conservatively, 3 often without the urgency toward diagnostic and therapeutic steps seen in those with other forms of MI.
Our evaluation of incident T2MI was based on a prospectively enrolled contemporary cohort of 1251 patients with detailed baseline clinical information, angiographic results, and a robust biorepository. In this analysis, incident T2MI during follow-up was more frequent than type 1 MI, and T2MI was often recurrent. In our cohort undergoing angiography, the majority of subjects experiencing T2MI possessing at least 30% obstruction of a major coronary artery at the time of index angiogram, indicating the importance of coronary obstruction for the genesis of subsequent T2MI. However, clinical predictors of T2MI suggest that this diagnosis possesses a complex medical phenotype; patients with T2MI had more extensive cardiac disease beyond the extent of coronary artery disease (including more prevalent HF) and substantially more medical comorbidities. Most gravely, the occurrence of T2MI strongly predicted subsequent adverse cardiac and noncardiac clinical outcomes even after adjusting for known risk factors. Indeed, patients having an incident T2MI had a similar or worse prognosis than those with incident type 1 MI. Because initial description in the second Universal Definition of MI, 12 data regarding T2MI have been slowly accumulating. However, determination of the exact definition, predictors, incidence, and meaning of T2MI has been challenging, with few studies prospectively seeking and adjudicating T2MI. In a randomized clinical trial of therapy for acute coronary syndrome, Morrow and colleagues reported that the incidence of T2MI was only 0.3% at 1 year, considerably less frequent than incident type 1 MI during this period. 13 In contrast, we found that the incidence of T2MI was significantly higher. These differences are likely explained by differences in baseline demographics and clinical risk factors between the 2 studies: in the Morrow and colleagues study, patients were from a randomized trial and subject to rigorous inclusion/exclusion criteria, and all patients received revascularization and aggressive medical therapy. This study presumably selected a generally lower-risk population of patients with less extensive coronary atherosclerosis and less complex comorbidity. The CASABLANCA study subjects were more representative of an all-comer population in comparison, at considerably higher risk for adverse outcome, and not subject to the inclusion/exclusion criteria of a randomized drug or revascularization trial. In addition, we used troponin rather than creatine kinase-MB as the main biomarker used to adjudicate T2MI, and therefore may have identified a larger number of events during follow-up; troponin has been shown to be more sensitive and specific for the diagnosis of MI than creatine kinase-MB and is the preferred biomarker for the diagnosis of MI. 8 Several schools of thought have developed regarding how exactly to define T2MI as per the Universal Definition. 1 Saaby and colleagues 14 have proposed more stringent criteria with additional specified conditions with decreased oxygen supply or increased oxygen demand; for example, anemia as a condition with decreased oxygen supply was defined as hemoglobin <5.5 mmol/L for men and <5.0 mmol/L for women, whereas Sandoval and colleagues 2 have proposed more individualized criteria with a requirement for an evident acute or sustained supply/ demand imbalance in the absence of other underlying conditions that lower the ischemic threshold, such as flow-limiting coronary artery disease and an individualized diagnostic approach in the presence of underlying conditions that lower the ischemic threshold. For our analysis, we adopted an approach more consistent with the latter definition at the time of adjudication to be as inclusive as possible, with the thought that further characterization and the link to prognostic information from this analysis may allow a more informed definition and categorization Hazard ratio is given per 1 standard deviation for continuous variables. CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
of T2MI. Our decision was also based on our clinical experience with T2MI; an individual patient's response to any given supply/demand mismatch condition may often be quite complex with wide variability in clinical phenotype. Indeed, apropos of this, we found a striking range of presentations, with a mixture of medical conditions such as gastrointestinal bleeding, respiratory ailments, and volume overload states, as well. We caution, however, that changes in troponin values alone do not appear to accurately differentiate between type 1 MI versus T2MI as articulated in the definition. 15 As discussed in a recent article, 16 clinician discretion is advised. Given the dominance of coronary artery disease in the genesis of T2MI, when such an event occurs, acute efforts to reduce acute supply/demand mismatch, optimization of coronary artery disease risk factors, and treatment for ischemic heart disease makes sense; it is also tempting to speculate that a revascularization-driven approach for affected patients might also be of benefit. However, the use of pharmacological therapies proven to reduce mortality in those with coronary artery disease was actually more frequent in those destined to develop T2MI, yet risk for mortality after T2MI was considerable despite an aggressive medical regimen. In this regard, the syndrome of T2MI may be too heterogeneous to be defined under a single classification, and further subdivision of T2MI may be needed to define appropriate therapies. 14 Baseline predictors of subsequent T2MI included a range of cardiovascular and noncardiovascular diseases, and the elevation in N-terminal pro-B-type natriuretic peptide (a biomarker of myocardial stress), cystatin C (a sensitive biomarker for renal dysfunction), and blood glucose. This ; accordingly, a single-treatment strategy may not necessarily benefit all those with T2MI. Efforts to better understand the heterogeneity of subjects experiencing T2MI in CASABLANCA are underway.
Our data are consistent with prior studies suggesting that T2MI is a highly morbid diagnosis with high risk for subsequent cardiovascular and all-cause death, similar to type 1 MI. 3, 18, 19 CASABLANCA differs from these prior studies, which were retrospectively performed, not designed to identify MI using Universal Definition Criteria, lacked a biorepository to identify biomarker predictors of future T2MI, and typically had significantly shorter follow-up. In addition, our follow-up not only identified first T2MI, but also gathered outcomes for each event; the observation that many subjects experienced repeated T2MI is novel and illustrates considerable morbidity in those affected. Last, we sought a broad range of cardiac, neurological, and renal complications during followup; the demonstration of the substantial risk for these various outcomes in those with T2MI makes CASABLAN-CA unique in comparison with prior analyses. 
Limitations
Despite the strengths of our analysis, there are several potential limitations. First, risk for misclassification exists, such that patients assigned a diagnosis of T2MI might have actually had a type 1 event. Such misclassification is inevitable in any study with the assignment of MI type by third party adjudication. Lending reassurance, we found 100% concordance with assigned T2MI diagnosis in a retrospective re-review. Furthermore, the misclassification of acute cardiac injury as T2MI might also have occurred; such acute cardiac injury is a poorly understood phenomenon, thought to occur via a noncoronary mechanism in many cases, but similarly associated with poor prognosis. Although prospectively collected with the intention to seek and study T2MI and with longer follow-up than many other studies, our cohort is still relatively small and representative of patients at a single urban tertiary care facility. Because our cohort is limited to patients undergoing angiography, the generalizability of our results has to be considered in this context; such patients a priori have higher pretest probability of coexisting heart disease, possibly increasing the magnitude of risk in our T2MI patients. However, the inclusion of patients with higher risk of significant coronary artery disease and type 1 MI would be expected to bias toward a relatively lower rate of T2MI in comparison with type 1 MI. We have used conventional rather than high-sensitivity troponin assay for the adjudication of MI diagnosis; the use of high-sensitivity troponin assay may increase the number of T2MI events identified in the future once these assays are commercially available in the United States; whether the definition of T2MI would require sex-specific troponin cutoffs remains unclear. Last, we lack the ability to inform treatment decision making; our data clearly illustrate the importance of characterization of those with T2MI to inform treatment strategies to reduce the considerable risk to which such patients are exposed.
In conclusion, among a population of patients undergoing coronary or peripheral angiography for a broad range of indications, incident T2MI was common and closely associated with poor prognosis. Prediction of future T2MI may be possible. Our study suggests that those with T2MI represent a morbid population of patients in need of multidisciplinary care to reduce their considerable cardiovascular and medical risk. Prospective randomized trials comparing the effectiveness of treatment strategies for T2MI are needed.
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